Literature DB >> 16250045

Infection of human hepatocyte chimeric mouse with genetically engineered hepatitis B virus.

Masataka Tsuge1, Nobuhiko Hiraga, Hideki Takaishi, Chiemi Noguchi, Hiromi Oga, Michio Imamura, Shoichi Takahashi, Eiji Iwao, Yoshifumi Fujimoto, Hidenori Ochi, Kazuaki Chayama, Chise Tateno, Katsutoshi Yoshizato.   

Abstract

Studies of hepatitis B virus (HBV) mutants have been hampered by the lack of a small animal model with long-term infection of cloned HBV. Using a mouse model in which liver cells were highly replaced with human hepatocytes that survived over a long time with mature human hepatocyte function, we performed transmission experiments of HBV. Human serum containing HBV and the virus produced in HepG2 cell lines that transiently or stably transfected with 1.4 genome length HBV DNA were inoculated. Genetically modified e-antigen-negative mutant strain also was produced and inoculated into the mouse model. A high-level (approximately 10(10) copies/mL) viremia was observed in mice inoculated with HBV-positive human serum samples. The level of viremia tended to be high in mice with a continuously high human hepatocyte replacement index. High levels and long-lasting viremia also were observed in mice injected with the in vitro generated HBV. The viremia continued up to 22 weeks until death or killing. Passage experiments showed that the serum of these mice contained infectious HBV. Genetically engineered hepatitis B e antigen-negative mutant clone also was shown to be infectious. Lamivudine effectively reduced the level of viremia in these infected mice. In conclusion, this mouse model of HBV infection is a useful tool for the study of HBV virology and evaluation of anti-HBV drugs. Our results indicate that HBeAg is dispensable for active viral production and transmission.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 16250045     DOI: 10.1002/hep.20892

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  54 in total

1.  Transplantation of human cells in the peritoneal cavity of immunodeficient mice for rapid assays of hepatitis B virus replication.

Authors:  Mukesh Kumar; Sriram Bandi; Kang Cheng; Sanjeev Gupta
Journal:  Xenotransplantation       Date:  2011 Nov-Dec       Impact factor: 3.907

2.  Humanized murine model for HBV and HCV using human induced pluripotent stem cells.

Authors:  Xiao-Ling Zhou; Gareth J Sullivan; Pingnan Sun; In-Hyun Park
Journal:  Arch Pharm Res       Date:  2012-02-28       Impact factor: 4.946

3.  Hepatitis B virus molecular biology and pathogenesis.

Authors:  R Jason Lamontagne; Sumedha Bagga; Michael J Bouchard
Journal:  Hepatoma Res       Date:  2016-07-01

4.  Hepatitis C virus dynamics and cellular gene expression in uPA-SCID chimeric mice with humanized livers during intravenous silibinin monotherapy.

Authors:  S DebRoy; N Hiraga; M Imamura; C N Hayes; S Akamatsu; L Canini; A S Perelson; R T Pohl; S Persiani; S L Uprichard; C Tateno; H Dahari; K Chayama
Journal:  J Viral Hepat       Date:  2016-06-08       Impact factor: 3.728

5.  A novel animal model for in vivo study of liver cancer metastasis.

Authors:  Shinsuke Fujiwara; Hikaru Fujioka; Chise Tateno; Ken Taniguchi; Masahiro Ito; Hiroshi Ohishi; Rie Utoh; Hiromi Ishibashi; Takashi Kanematsu; Katsutoshi Yoshizato
Journal:  World J Gastroenterol       Date:  2012-08-07       Impact factor: 5.742

6.  Efficacy of hepatitis B virus ribonuclease H inhibitors, a new class of replication antagonists, in FRG human liver chimeric mice.

Authors:  Kelly R Long; Elena Lomonosova; Qilan Li; Nathan L Ponzar; Juan A Villa; Erin Touchette; Stephen Rapp; R Matt Liley; Ryan P Murelli; Alexandre Grigoryan; R Mark Buller; Lisa Wilson; John Bial; John E Sagartz; John E Tavis
Journal:  Antiviral Res       Date:  2017-11-10       Impact factor: 5.970

7.  Activity of nucleic acid polymers in rodent models of HBV infection.

Authors:  Katrin Schöneweis; Neil Motter; Pia L Roppert; Mengji Lu; Baoju Wang; Ingo Roehl; Dieter Glebe; Dongliang Yang; John D Morrey; Michael Roggendorf; Andrew Vaillant
Journal:  Antiviral Res       Date:  2017-11-08       Impact factor: 5.970

8.  Acute hepatitis B virus infection in humanized chimeric mice has multiphasic viral kinetics.

Authors:  Yuji Ishida; Tje Lin Chung; Michio Imamura; Nobuhiko Hiraga; Suranjana Sen; Hiroshi Yokomichi; Chise Tateno; Laetitia Canini; Alan S Perelson; Susan L Uprichard; Harel Dahari; Kazuaki Chayama
Journal:  Hepatology       Date:  2018-06-06       Impact factor: 17.425

9.  Persistent Loss of Hepatitis B Virus Markers in Serum without Cellular Immunity by Combination of Peginterferon and Entecavir Therapy in Humanized Mice.

Authors:  Takuro Uchida; Michio Imamura; C Nelson Hayes; Nobuhiko Hiraga; Hiromi Kan; Masataka Tsuge; Hiromi Abe-Chayama; Yizhou Zhang; Grace Naswa Makokha; Hiroshi Aikata; Daiki Miki; Hidenori Ochi; Yuji Ishida; Chise Tateno; Kazuaki Chayama
Journal:  Antimicrob Agents Chemother       Date:  2017-08-24       Impact factor: 5.191

10.  A human hepatocyte-bearing mouse: an animal model to predict drug metabolism and effectiveness in humans.

Authors:  Katsutoshi Yoshizato; Chise Tateno
Journal:  PPAR Res       Date:  2009-10-26       Impact factor: 4.964

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.